Phaseline

Companies › NSC-Therapeutics

NSC-Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NSC001
M1 muscarinic receptor agonist
CHRM1Phase 1Alzheimer Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06995573NSC001Phase 1Alzheimer DiseaseNeurologyJul 2026

Targets

CHRM1 (1)

Companies with the same targets

Bristol-Myers Squibb Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Anavex Life Sciences Ocus Innovation Ireland Novartis AstraZeneca ACADIA Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.